ArticleRenal failure2025
Optimizing α-galactosidase A enzyme cutoff for Fabry disease screening in chronic kidney disease patients: a single-center reassessment of diagnostic yield and cost-effectiveness.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fabry disease has been increasingly recognized in patients with chronic kidney disease (CKD). While dried blood spot (DBS) testing for α-galactosidase A (α-Gal A) activity is a common screening method, the optimal cutoff value for enzyme activity in this population remains uncertain. We retrospectively analyzed data from a Fabry disease screening program conducted between October 1, 2018, and September 31, 2023, at Taichung Veterans General Hospital. Male patients with CKD or ESKD underwent DBS α-Gal A enzyme activity testing. Patients with enzyme activity <2.0 μmol/L/hr were referred for confirmatory genetic testing. We assessed the diagnostic yield, baseline characteristics of true positive, false positive, and true negative cases, and performed receiver operating characteristic (ROC) analysis to identify the optimal diagnostic threshold. Among 1,654 screened patients, 35 had enzyme activity <2.0 μmol/L/hr, of whom 6 (0.36%) were genetically confirmed as having Fabry disease. Broadening the screening threshold from 1.2 to 2.0 μmol/L/hr enabled the identification of two additional cases. ROC analysis identified an optimal cutoff value of 1.96 μmol/L/hr (AUROC 0.996, 95%CI: 0.991-1.000), yielding a sensitivity of 98.3% (95CI%: 0.9769-0.9891) and specificity of 100% (95%CI:1-1). Patients with false-positive results had significantly lower leukocyte counts than true-positive cases. The incremental cost to detect two additional Fabry patients was $8,010 USD, representing acceptable cost-effectiveness under Taiwan's healthcare framework. Expanding α-Gal A enzyme activity cutoff value from 1.2 to 2.0 μmol/L/hr improved the diagnostic performance of Fabry disease screening in CKD patients and proved to be cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.